CBIO Secures $12.5M funding from SpringTree1 June 2010 – CBIO
(ASX:CBZ), MD & CEO, Jason Yeates discusses the terms of the SpringTree Special Opportunities Fund Convertible Loan Agreement and where the funding will go. Also covered; the XToll trial and recruitment of the 75th patient , $1M milestone payment from option holder Danish pharmaceutical company Novo Nordisk and the CBIO share purchase plan.
